Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-29

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The object of this study is to evaluate the pharmacokinetic interactions, short term safety and efficacy of standard dose lopinavir/ritonavir 200mg/50 (two tablets twice daily) given with ritonavir 100 mg three tablets twice daily given in combination with rifampin in HIV-infected persons with tuberculosis

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin

NCT00771498

HIV Infection Tuberculosis

COMPLETED PHASE4

Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB

NCT02348177

Acquired Immunodeficiency Syndrome Tuberculosis

COMPLETED PHASE4

Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy

NCT01138202

HIV Infections Tuberculosis

COMPLETED PHASE2

The Effect of Intermittent Rifampicin on Raltegravir

NCT01424826

HIV Tuberculosis

COMPLETED PHASE1

A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers

NCT03199690

HIV-1-infection Tuberculosis

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will be an open label non-randomized pharmacokinetic study of 10-12 HIV-infected patients co-infected with Mycobacterium tuberculosis.

Enrollment: Potential subjects with active tuberculosis who have tolerated a rifampin containing regimen for at least 2 weeks. Potential subjects will be referred from the surrounding communities to Laboratorio de Pesquisa Clinica em Micobacterioses(LAPCLINTB)

Visit 1: Subjects will then be started on lopinavir/ritonavir containing HAART regimen with standard twice daily dosing. Ritonavir 100 mg capsules will be added to the regimen and the dose escalated until the patient is taking 3 capsules twice daily. The time between enrollment and visit 1 will be determined by the treating physician.

Visit 2: They will return about 1 week after dose escalation has been completed to sample lopinavir and rifampin concentrations.

Visit 3: Subject will return in 2 weeks to have repeat to review results of lopinavir concentrations and response to therapy. Ritonavir will be adjusted as needed.

Visit 4: Subject will then return in 4 weeks for last visit for evaluation. Lopinavir and rifampin PK will be done.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

AIDS Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lopinavir/ritonavir and ritonavir

Two tablets of twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 tablets of ritonavir 100 mg of twice daily given with rifampin 600 mg daily.

Group Type EXPERIMENTAL

Lopinavir/ritonavir and ritonavir

Intervention Type DRUG

Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lopinavir/ritonavir and ritonavir

Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Kaletra Norvir

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be at least 18 years of age and able to give informed consent.
* Diagnosed with TB by criteria per Brazilian Ministry of Health
* Have a good clinical response to TB.
* Tolerating tuberculosis therapy containing rifampin for the 2 weeks prior to screening,except for persons taking protease inhibitors at time of diagnosis of TB.,. Subjects taking protease inhibitors will be screened and initiate visit 1 within 3 days of starting TB medication
* HIV positive with documentation present in source document.
* Have a CD4 cell count greater than 50 cells/mm3if not taking ART. Persons with cd4 \< 50 may be enrolled, if it is felt that in the best interest of the patient, that enrollment in the study will allow for quicker initiation of antiretroviral therapy than referral to another treatment center.

Exclusion Criteria

* Non-compliance with DOTPlus. Alternatively DOT can be done by telephoning patient on a daily basis 5 times a week and having patient annotate taking drug in a log which would be reviewed by clinic staff
* History of being treated for tuberculosis in the prior 2 years unless there is DST, including PCR testing, showing sensitivity to rifamycin.
* Known hypersensitivity to rifampin or rifabutin.
* Liver enzymes greater than 2 times ULN.
* Bilirubin greater than 2 times ULN.
* Serum creatinine greater than 3 times ULN.
* Hemoglobin less than 7.0 gms even if receiving erythropoietin.
* Absolute neutrophil count less than 750 cells/mm3 even if receiving G-CSF.
* Fasting triglycerides greater than 400 mg/dL.
* Fasting cholesterol \> 1.6 upper limits of normal.
* GI intolerance of tuberculosis medications requiring discontinuation of tuberculosis medications.
* Fasting glucose greater 150 mg/dL.
* Pregnant women.
* Use of one of the prohibited medications
* Any condition that the investigators feel could compromise the use of the current medication.
* Have a CD4 cell count of 50 cells/mm3or less
* Hepatitis B or C infection
* Alcohol or illicit drug use, which in the investigators opinion may affect participation in study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No